Background: PD-L1 immunohistochemistry (IHC) testing is usually carried out on tissue blocks from core needle biopsy or surgical resections. In this study, we assessed the feasibility of using cytology cell blocks for PD-L1 IHC assay.
Introduction
Advanced lung cancer is the first cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers. Except 20%-30% of NSCLC that harbor actionable molecular alterations and can be treated with targeted tyrosine kinase inhibitors, most of NSCLC patients were traditionally treated with platinum-based chemotherapy and/or radiation therapy [1] . The introduction of immune checkpoints inhibitors has changed the standard of care of advanced NSCLC [2] [3] [4] . Programmed cell death ligand-1 (PD-L1) is an immune checkpoint protein expressed on tumor cells and tumorinfiltrating immune cells [5] . Binding PD-L1 to PD-1 receptors and other binding partners, such as B7.1 (CD80) present at the surface of antigen presenting cells and activated B cells, allows tumor cells escape from T cell surveillance. In recent years, several anti-PD-L1 or PD-1 humanized antibodies have been developed to block the interaction between PD-L1 and PD-1 and to restore T-cell antitumor functions. Multiple randomized clinical trials have shown their significant impact on overall survival in second and first line [6, 7] . KEYNOTE 001 study clearly demonstrated that clinical response with pembrolizumab correlates with PD-L1 immuno-expression in tumor cells [8] . The percentage of stained viable tumor cells over total tumor cells (tumor proportion score, TPS) !50% is associated with higher response rate and overall survival compared with patients with lower TPS (<50%). More recently, KEYNOTE 024 study showed that Pembrozilumab was superior to chemotherapy as a first-line treatment of patients with TPS !50% [2] . Pembrozilumab was subsequently approved by FDA as a first-line treatment of PD-L1 positive NSCLC [1] . All those clinical trials required either a core needle biopsy or surgical resection to evaluate PD-L1 immuno-expression in tumor cells.
Around 80% of advanced NSCLC patients will only have tissue from small biopsies or cytology and as many as 31% of patients do not have adequate tissue making them ineligible for clinical trials [9] . Excluding cytology specimens from predictive immunohistochemistry (IHC) assays lead to additional sampling procedures in these frail patients with associated morbidity and costs, or to exclude patients for potentially effective treatments. So far, experience of PD-L1 IHC assay in cytology specimens is scarce and no large longitudinal study has been reported [10] [11] [12] [13] [14] . The purpose of this study is to assess the feasibility of PD-L1 immunostaining in cytology cell blocks in a reference testing center.
Material and methods

Patients and specimens
A total of 1419 consecutive specimens with an initial diagnosis of NSCLC sent to the Jewish General Hospital (JGH) between June 2016 and April 2017 were included in this study. The study cohort included 371 cytology cell blocks, 809 small biopsies and 239 surgical resections. The small biopsy category included core needle biopsy, endobronchial biopsy, or punch biopsy of skin metastases. The cytology specimens included endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA, n ¼ 186), endoscopic ultrasound-guided fine needle aspiration (EUS-FNA, n ¼ 5), fine needle aspiration (n ¼ 61), pleural/pericardial fluid (n ¼ 79) and bronchoalveolar lavage (BAL, n ¼ 11); Twenty-nine (8%) cell blocks did not have remaining material and were not tested in the study.
The fixation was known for 261 (76%) cytology specimens. Four types of fixation methods were used in cytology specimens: 112 (43%) specimens were fixed with CytoLyt (Hologic Inc., Marlborough, MA) or alcohol followed by 10% buffered neutral formalin (BNF), 78 (30%) specimens were fixed with 10% BNF only, 51 (20%) cases were fixed with TissuFix (Chaptec INC, Montreal, Canada, 6% formaldehyde with 2% methyl alcohol), and 20 (7%) cases were fixed with CytoLyt or 50% alcohol only. The preparation of cell blocks was as follows: fluid cytology samples were span down and the pellets were mixed with HistoGel (American MasterTech, Lodi, CA) and after solidification were embedded into paraffin blocks. The histologic samples were embedded into paraffin after fixation in 10% BNF. The overall fixation time for all types of specimens was between 12 and 84 h depending on week day or weekend (80% within 24 h for cytology or small biopsy specimens and within 24-72 h for surgical specimens). A total of 27 pairs made of at least one cytology and one histology sample done in the same patient during a 2-month interval period were available.
All tissue or cell blocks were then cut into 4 lm thick sections and then stained with Dako PD-L1 22C3 PhamDx (Dako North America Inc., Carpinteria, CA) according to manufacturer's instruction [11] . Sections were baked and deparaffinized, followed by antigen retrieval, then stained on Dako Link autostainer system. Controls were prepared for each sample; positive controls were cell blocks provided by the vendor and negative controls were the histology or cytology specimen without primary antibody.
PD-L1 immunohistochemistry scoring
All stained slides were independently reviewed by two experienced pathologists (HW, AS). Difficult cases were resolved by consensus. Specimens were considered adequate if a total of 100 or more viable tumor cells were present. Tumor cells were scored for PD-L1 expression as previously reported [8] . As per recommendations, tumor cells with weak (1þ), moderate (2þ) or strong (3þ) partial or complete membranous staining were counted as stained cells. Tumor proportion score (TPS) was used to categorize the specimens into three groups: TPS <1% (negative), 1%-49% (low expression) and !50% (high expression) ( Figure 1 ).
Statistical analysis
Proportion of PD-L1 TPS positivity among sample types and other predictive biomarkers (presence or not of mutations in EGFR and KRAS, EML4-ALK translocation) were compared using v 2 Independence test. A multivariate analysis was carried out using a logistic regression model to explore the association of PD-L1 expression with sample characteristics (type of specimens, site of biopsy, age of specimens). The TPS scores in histology and cytology in paired samples were compared with paired samples t test. Statistical analyses were carried out by using IBM-SPSS Statistics version 24 (IBM Corp., Armonk, NY, USA). P < 0.01 was considered as significant.
Results
Adequacy of different types of specimens PD-L1 was successfully evaluated in 1326/1419 (93%) specimens (supplementary Table S1 , available at Annals of Oncology online). All 239 surgical specimens were adequate for PD-L1 testing. Among 371 cytology and 809 small biopsy specimens, 92% in each category were found adequate for PD-L1 testing. No significant difference in adequacy was found between specimen types.
PD-L1 expression in different types of specimens
Overall, PD-L1 expression with cut-off of TPS 50% and 1% was in 36% and 71% of samples, respectively. The rate of PD-L1 expression in different specimen types is shown in Table 1 . The rate of PD-L1 expression with TPS !50% was significantly higher in cytology specimens when compared with surgical specimens (P ¼ 0.001) or slightly higher when compared with small biopsy (P¼ 0.04). There was no significant difference between small biopsy group and surgical resection group. Since the fixation time differed between small biopsies and surgical resections, we evaluated whether the fixation types influenced the proportion of high TPS and TPS taken as a continuous variable. No significant correlation was found. In the 27 pairs of cytology and histology samples, TPS scores were significantly positively correlated (r ¼ 0.925, P < 0.001).
PD-L1 expression correlation with different lung cancer histology
We defined squamous cell carcinomas as pure squamous cell carcinoma, or combined carcinoma with squamous but not adenocarcinoma components. Non-squamous carcinomas included adenocarcinoma defined as any pure or combined tumor with adenocarcinoma components, and non-adenocarcinoma/nonsquamous carcinoma. Non-squamous carcinoma was the most frequent histology (84%) and most of them were adenocarcinomas (92%). The overall rate of high PD-L1 expression (TPS ! 50%) was similar in squamous versus non-squamous cell carcinoma (32% versus 37%, NS) (see Table 2 ). In adenocarcinomas, the rate of PD-L1 ! 50% was higher in cytology specimens than in resection specimens (43% versus 27%, P ¼ 0.002), but not in squamous cell carcinomas.
PD-L1 expression in cytology cell blocks and fixation
Most of the cytology specimens (n ¼ 283, 85%) were from metastatic sites of the disease and only 15% were from the lung primary tumor. The PD-L1 high expression rate did not differ significantly between lung and metastasis specimens (42% versus 41%). Among 261 cytology specimens with known fixation status, the fixation process (formalin only versus methanol/alcohol only versus both) did not affect the PD-L1 staining. The high PD-L1 expression rate was 42% in formalin fixation only and 40% in combined fixation by methanol/alcohol and formalin.
Factors associated with PD-L1 positivity
Factors associated with PD-L1 expression were studied in a subset of 483 specimens with known pathological stage of the disease. The following factors were selected for analysis: type and age of specimens, stage of disease. The age of the specimens was included to determine whether PD-L1 expression could get lost over the years of storage. In univariate analysis, the specimen type (P ¼ 0.02) and stage (P < 0.001) were significantly associated with PD-L1 high expression. The age of the specimen did not affect the immunohistochemical staining (Table 3) .
In multivariate analysis, the stage of the disease was the only variable significantly associated with PD-L1 positivity (Table 3) . PD-L1 high expression (TPS !50%) rate was 2.3-fold higher (95% CI: 1.39-3.81) in metastatic cancer as compared with early/ locally advanced stage. After adjustment for stage, PD-L1 positivity rate was not significantly affected by the type of the specimen.
Correlation of PD-L1 expression with EGFR/KRAS/ EML4-ALK status
EGFR status was known in 801 non-squamous carcinoma specimens. Among those, 82 (10%) had mutation(s). Twenty-five out of the 82 (30%) had PD-L1 TPS !50%. Among 909 nonsquamous carcinoma specimens with known ALK status, 10 (1%) had an EML4-ALK translocation. Three of them showed diffuse PD-L1 staining (supplementary Figure S1 , available at Annals of Oncology online). Overall, there was no correlation between EGFR, ALK, KRAS status and high expression of PD-L1 Figure 1 . Examples of PD-L1 immunocytochemical staining on EBUS-TBNA cytology cell block from mediastinal lymph node using 22C3PhamDx kit. (A) TPS <1%; (B) TPS 1%-49%; (C) TPS 90% (Â200 magnification). Table 1 . PD-L1 expressions in different types of specimens (TPS !50%) (supplementary Table S2 , available at Annals of Oncology online).
Discussion
In this study, most of the cytology specimens had adequate viable tumor cells for PD-L1 testing that were comparable with small biopsies. Similar to small biopsies, the failed cases were mainly the specimens for which prior EGFR/ALK testing done in another institution had exhausted tumor material. This underlines the importance of doing PD-L1 IHC at the same time as other molecular tests since checkpoint inhibitors are now first line therapy. The 22C3 clone was used in this study based on the approval of Pembrolizumab in second line of advanced NSCLC with high PD-L1 immunoexpression, but other reagents will have to be evaluated in cytology samples and compared with 22C3. The overall PD-L1 expression in our study was close to the KEYNOTE 024 study with a reported 30% positivity rate at a cutoff of 50% [2] . The rate of high expression of PD-L1 (!50%) is slightly higher in cytology specimens compared with small biopsies but significantly higher if compared with surgical resection specimens. The difference persists even when the tumor stage is introduced in the model. In a previous study, Skov et al. also observed a higher prevalence positivity rate with 22C3 clone and a cut-off of 50% in cytology than in histology specimens [11] .
Interestingly, in our study this difference was only seen in the adenocarcinoma group. In their 86 paired samples of NSCLC with both histological blocks and cytology material, they reported an overall agreement of 94% with the 22C3 clone. It is not clear why the cytology cell blocks were more often associated with high PD-L1 expression than surgical resections in our study. Some preanalytical factors such as suboptimal fixation of surgical resection specimens may contribute to it [15] . In general, surgical resection specimens are more likely to have delayed fixation or over fixation compared with cytology cell block or small biopsy. However, we do not have detailed data of ischemia time or exact fixation time for surgical resections in the current study. It has been reported that PD-L1 expression fade with time [16] . In our study, even though the surgical resections specimens were older than cytology or biopsy specimens, the age of paraffin block did not significantly influence PD-L1 expression. Previous studies had found that PD-L1 expression varies by tumor stage with higher expression in more advanced lung adenocarcinoma [17] . This is supported by our result, and a multivariate analysis showed that the effect of the specimen type disappears after control of the clinical stage. Only staging was found to associate with high PD-L1 expression. It is possible that the tumor cells upregulate their PD-L1 expression when they metastases in order to escape from immune surveillance.
Alcohol/methanol-based fixation has been reported to affect the immunohistochemical staining in cytology specimens [18- 21]. It mainly affected the nuclear staining such as ER, PR or TTF-1 with weaker level of protein expression. The membranous or cytoplasmic staining seems less affected by alcohol fixation [22] [23] . In this study, we assessed the effect on PD-L1 IHC of 10% buffered formalin only, methanol/alcohol only versus prefixation with Cytolyt/alcohol followed by 10% formalin. We did not find difference of PD-L1 expression, nor in morphology, with or without Cytolyt/alcohol pre-fixation. Our result is different from the experience from Alex's group who found decreased PD-L1 expression in Cytolyt fixed cytology cell blocks [21] . It is possible that most of our cases with both fixatives had short methanol/alcohol pre-fixation time and few cases were fixed with CytoLyt/alcohol only. However, overall, 10% formalin is preferred fixative for PD-L1 testing in lung cancer. Similar to previous studies [3, 17, 24] , we found that PD-L1 expression was not related to EGFR and ALK-1 status. However, different from previous studies, we did not find any significant correlation between PD-L1 expression and KRAS status [25] .
Compared with large surgical specimens or biopsies, the PD-L1 immunostaining in cytology specimens is more challenging to interpret. In EBUS/EUS/FNA specimens, the tumor cells are usually very cohesive with either glandular or solid growth patterns and are similar to biopsy specimens. In fluid cytology, tumor cells can be difficult to differentiate from mesothelial cells and macrophages. However, luckily they often form cohesive clusters in contrast to single mesothelial cells or macrophages. When they present as single cells, most of the time, the tumor cells are very pleomorphic with high-grade malignancy morphology. Evaluating the nuclear features and frequently comparing with hematoxylin/eosin (H&E) stained slides are the most useful approaches to make this distinction and are not interfered by PD-L1 membranous staining. In rare situations, when tumor cells have low-grade cytomorphology, additional immunocytochemical stains with anti-TTF-1 or anti-BerEp4 can be useful. In our study, $10% of cases were challenging with TPS around cutoff either 1% or 50% (610% TPS, data not shown). Most of the cytology cases have TPS away from cutoff, which makes them less difficult to interpret. We found agreement can be achieved among pathologists with practice. Recently, several studies have looked into the inter-observer interpretation variation in surgical resection specimens with good kappa values [26, 27] . In future, it may be interesting to evaluate the inter-pathologist variability on cytology specimens and to include these specimens in consensus sessions.
In conclusion, cytology specimens are suitable for PD-L1 immunohistochemical staining testing. Although the interpretation can be more challenging that in tissue specimens, it is an important resource for PD-L1 testing and can spare additional interventions in frail patients. Future study to compare the predictive value of cytology and biopsy specimens for clinical response to immune therapy will be important for definitive validation of cytology specimens.
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